Compugen Ltd
CGEN
Get informed when a big investor buys or sells
+ FollowMarket Cap$190.05M
Close$
$2.54
26.5% upside
Current Fair Value
26.5% upsideUndervalued by 26.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $190.05 Million |
|---|---|
| Enterprise Value | $192.15 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.38 |
| Beta | 2.74 |
| Outstanding Shares | 94,556,230 |
Return
| Return on Equity | 36.55% |
|---|---|
| Return on Assets | 23.90% |
| Return on Invested Capital | 27.52% |
Valuation & Multiples
| P/E Ratio | 5.48 |
|---|---|
| PEG | 80.61 |
| Price to Sales | - |
| Price to Book Ratio | 2.01 |
| Enterprise Value to Revenue | 2.64 |
| Enterprise Value to EBIT | 5.64 |
| Enterprise Value to Net Income | 5 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.15 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 18, 2026
EPS Estimate
$-0.07
Average shareholder expectationRevenue Estimate
$1.57 M
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$-0.07
Average shareholder expectationRevenue Estimate
$1.28 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 123,900▲ Infinity% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 15.19%▲ 1.72% |
|---|---|
| Total Invested | $30.87M▲ 56.50% |
| Investors Holding | 79▲ 7.00% |
ESG Score
No data
About Compugen Ltd
CEO: Anat Cohen-Dayag Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immu...